Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Taysha Gene Therapies Q3 2026 Results: Net Loss of $39.1M, Loss Widens

Taysha Gene Therapies reported a net loss of $128.2 million for the nine months ended September 30, 2026, compared to $81.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten public offering that raised approximately $215.7 million, ending the period with $422.8 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-39.1-32.7
EPS (diluted, $ a share)$-0.10$-0.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TSHA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Taysha Gene Therapies, Inc.: key numbers

Share price
$4.06Close, Nov 16
Market cap
$1.32B
Shares outstanding
326.05MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Taysha Gene Therapies, Inc.

All →
7:38 AM ET 8-K
Financial Results

Taysha Gene Therapies Financial Results

Taysha Gene Therapies reported third quarter 2026 financial results and provided a corporate update on its TSHA-102 gene therapy program for Rett syndrome. The company completed its BLA-enabling manufacturing campaign and expects to report topline 6-month interim data and receive FDA feedback on its BLA submission pathway in the first half of 2027.

“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome.”

Sean P. Nolan, Chairman and Chief Executive Officer of Taysha

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.